Phase I dose-escalation study of XL147, a PI3K inhibitor administered orally to patients with solid tumors
作者： G. Shapiro , E. Kwak , J. Baselga , J. Rodon , C. Scheffold
DOI: 10.1200/JCO.2009.27.15_SUPPL.3500
关键词:
摘要: 3500 Background: XL147 is a selective inhibitor of Class I PI3K isoforms. In preclinical cancer models cytostatic or cytoreductive as monotherapy and enhances the efficacy targeted agen...
sci-hub.st 参考文章(0)